Moreover, HER2TCR−NKp30+CD8+ T cells degranulated in response to the tumor cell line, in a TCR-independent manner (Figure 3(f)), as we have previously shown.23 Importantly, the introduction of the HER2-specific TCR (HER2TCR+NKp30+) markedly increased the response of NKp30+CD8+ T cells (Figure 3(f)). This evidence concerns the gene ERBB2 and neoplasm.